Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Haemonetics (HAE) Research & Development (2016 - 2025)

Haemonetics has reported Research & Development over the past 17 years, most recently at $14.2 million for Q4 2025.

  • For Q4 2025, Research & Development fell 10.37% year-over-year to $14.2 million; the TTM value through Dec 2025 reached $63.6 million, up 5.56%, while the annual FY2025 figure was $62.7 million, 15.22% up from the prior year.
  • Research & Development for Q4 2025 was $14.2 million at Haemonetics, down from $14.9 million in the prior quarter.
  • Over five years, Research & Development peaked at $18.3 million in Q1 2025 and troughed at $10.0 million in Q1 2022.
  • A 5-year average of $13.5 million and a median of $13.2 million in 2022 define the central range for Research & Development.
  • Biggest five-year swings in Research & Development: skyrocketed 63.88% in 2021 and later decreased 14.16% in 2022.
  • Year by year, Research & Development stood at $10.9 million in 2021, then rose by 16.92% to $12.7 million in 2022, then grew by 4.54% to $13.3 million in 2023, then increased by 19.33% to $15.8 million in 2024, then fell by 10.37% to $14.2 million in 2025.
  • Business Quant data shows Research & Development for HAE at $14.2 million in Q4 2025, $14.9 million in Q3 2025, and $16.3 million in Q2 2025.